Eli Lilly and Company

• 10-QQ2 FY2026PositiveImpairment / charge

  Filed Aug 5

  Mounjaro and Zepbound volume, especially abroad, outweighed lower realized prices; acquisition charges tempered earnings growth.

  • Revenue$23.0BYoY +47.7%
  • Net income$7.1BYoY +25.3%

• 8-KPositiveEarningsGuidance loweredImpairment / charge

  Filed Aug 5

  Mounjaro and Zepbound volume drove higher revenue and margin guidance despite price declines; acquired IPR&D charges lowered the EPS outlook.

• 8-KDebt financing

  Filed May 20

  Debt offering completed; several note series must be redeemed if the Centessa acquisition misses its closing deadline or is abandoned.

• 8-KShareholder vote

  Filed May 7

  Proposals to end the classified board and supermajority voting fell short of the 80% outstanding-share approval threshold.

• 10-QQ1 FY2026Positive

  Filed Apr 30

  Mounjaro and Zepbound volume outweighed lower prices; Foundayo’s U.S. approval adds an oral obesity option.

  • Revenue$19.8BYoY +55.5%
  • Net income$7.4BYoY +168.1%

• 10-KFY2025PositiveImpairment / charge

  Filed Feb 12

  Mounjaro and Zepbound volume drove growth despite lower realized U.S. prices; Lilly is expanding manufacturing capacity.

  • Revenue$65.2BYoY +44.7%
  • Net income$20.6BYoY +94.9%

• 8-KPositiveEarningsNew guidance

  Filed Feb 4

  Mounjaro and Zepbound volume growth drove sales higher, partly offset by lower realized prices.

Coverage: 10-K filings filed since Feb 12, 2026; 10-Q since Apr 30, 2026; 8-K since Feb 4, 2026.

Request longer coverage

Company data: Wikidata Q632240